Reviewer's report

Title: Evaluation of Efalizumab using Safe Psoriasis Control

Version: 2 Date: 4 July 2006

Reviewer: Steven Feldman

Reviewer's report:

General

-------------------------------------------------------------------------------

Major Compulsory Revisions
1. The Purpose of the study and the Conclusion are incongruous. The Purpose reads as an assessment of an instrument. The Conclusion reads as an assessment of a drug. There's nothing (or at most very little) new here about the drug. There's nothing new about the validity of the SPC measure, either, as far as I can tell.

-------------------------------------------------------------------------------

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)
Consider changing "has been shown to" and its various other forms to "is"

-------------------------------------------------------------------------------

Discretionary Revisions (which the author can choose to ignore)
There ought to be more than a poster reference for the Koo-Menter instrument.

What next?: Accept after minor essential revisions

Level of interest: An article of limited interest

Quality of written English: Acceptable

Statistical review: No

Declaration of competing interests:
I've had funding from about all the companies with drugs for psoriasis, including Genentech and their competitors.